Drugs / CKD-516
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01560325 | Jun 2012 → Oct 2014 | cancer of unknown primary site | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT01028859 | Dec 2009 → Apr 2011 | cancer of unknown primary site | Chong Kun Dang Pharmaceutical | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04696848 | Feb 2021 → Mar 2023 | colorectal cancer | Tae Won Kim | Terminated | No outcome recorded |
| Phase 1/2 | NCT03076957 | Dec 2016 → Jun 2018 | colorectal cancer | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-516 | “CKD-516” NCT03076957 ↗ |
| Modality | Other / unclassified | “CKD-516, a novel vascular disrupting agent” PMID 33829355 ↗ Apr 2021 |
| Route | Intravenous | “Patients receive CKD-516 IV over 30 minutes on day 1, 8 every 3 weeks” NCT01028859 ↗ |